Aside from these clinical trials, there are also some other ongoing trials combining IDO inhibitor and immunotherapy in melanoma, for example, the combination of IDO inhibitor indoximod and ipilimumab/nivolumab/pembrolizumab (NCT02073123). Here, IDO1 is linked to melanoma.